2. Search Result
Search Result
Results for "

peptic

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108287
    Trithiozine

    		Others Endocrinology
    Trithiozine is an orally active antisecretory and antiulcer agent. Trithiozine can be used for the research of peptic ulcer disease and hypersecretory disorders .
    Trithiozine
  • HY-162149
    Urease-IN-12

    		Bacterial Infection
    Urease-IN-12 (compound 5e) is a competitive urease inhibitor (IC50: 0.35 μM) with the potential to inhibit gastritis and peptic ulcer caused by Helicobacter pylori .
    Urease-IN-12
  • HY-162139
    Urease-IN-11

    		Bacterial Inflammation/Immunology
    Urease-IN-11 (Compound 6e) is a competitive urease inhibitor (IC50)=10.41 µM). Urease-IN-11 can be used to study diseases such as urease-related gastritis and peptic ulcer .
    Urease-IN-11
  • HY-155970
    Urease-IN-7

    		Bacterial Infection Inflammation/Immunology
    Urease-IN-7 (Compound 5k) is a competitive Urease inhibitor (IC50: 3.33 μM, Ki: 3.62 μM). Urease-IN-7 can be used for research of peptic and gastric ulcers .
    Urease-IN-7
  • HY-155973
    Urease-IN-8

    		Bacterial Infection Inflammation/Immunology
    Urease-IN-8 (Compound 5e) is a competitive Urease inhibitor (IC50: 3.51 μM, Ki: 3.11 μM). Urease-IN-8 can be used for research of peptic and gastric ulcers .
    Urease-IN-8
  • HY-B0955
    Oxethazaine
    1 Publications Verification

    Oxetacaine

    		 HBV Neurological Disease
    Oxethazaine (Oxetacaine), a precursor of phentermine acidic, is an acid-resistent and orally active analgesic agent. Oxethazaine (Oxetacaine) has the potential for the relief of pain associated with peptic ulcer disease or esophagitis .
    Oxethazaine
  • HY-17037
    Pirenzepine dihydrochloride
    1 Publications Verification

    LS 519; Pirenzepin dihydrochloride; Gastrozepin dihydrochloride

    		 mAChR Metabolic Disease Cancer
    Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .
    Pirenzepine dihydrochloride
  • HY-W003467
    Rabeprazole Sulfide

    		Proton Pump Bacterial Infection Inflammation/Immunology
    Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H +/K +)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment .
    Rabeprazole Sulfide
  • HY-136338
    Cimetidine sulfoxide

    Cimetidine sulphoxide

    		 Histamine Receptor Inflammation/Immunology
    Cimetidine sulfoxide (Cimetidine sulphoxide) is a sulfoxide metabolite of Cimetidine. Cimetidine is a histamine H2-receptor antagonist. Cimetidine has the potential for peptic ulcer disease and upper gastrointestinal haemorrhage treatment .
    Cimetidine sulfoxide
  • HY-B1806A
    Tridihexethyl chloride

    Pathilon chloride

    		 mAChR Neurological Disease Inflammation/Immunology
    Tridihexethyl (Pathilon) chloride is an orally active anticholinergic agent and mAChR antagonist, shows activities of antimuscarinic and anticholinergic. Tridihexethyl chloride shows pronounced antispasmodic and antisecretory effects on the gastrointestinal tract. Tridihexethyl chloride can be used in studies of peptic ulcer disease and acquired nystagmus .
    Tridihexethyl chloride
  • HY-17037S1
    Pirenzepine-d8 dihydrochloride

    LS 519-d8 dihydrochloride; Pirenzepin-d8 dihydrochloride; Gastrozepin-d8 dihydrochloride

    		 Isotope-Labeled Compounds Cancer
    Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .
    Pirenzepine-d8 dihydrochloride
  • HY-145578
    Linaprazan glurate

    X842

    		 Others Inflammation/Immunology
    Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate exhibits several advantageous properties, such as fast onset, high in vivo potency and/or long duration of action. Linaprazan glurate is useful in the research of gastrointestinal inflammatory diseases and peptic ulcer diseases (extracted from patent WO2010063876A1) .
    Linaprazan glurate
  • HY-101694
    Siltenzepine

    		Others Inflammation/Immunology
    Siltenzepine is an anti-acid agent. It is used in the treatment of peptic ulcers.
    Siltenzepine
  • HY-15295
    Vonoprazan Fumarate
    3 Publications Verification

    TAK-438

    		 Proton Pump Metabolic Disease
    Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .
    Vonoprazan Fumarate
  • HY-100007A
    Vonoprazan hydrochloride

    TAK-438 hydrochloride

    		 Proton Pump Bacterial Infection Endocrinology
    Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .
    Vonoprazan hydrochloride
  • HY-107590
    GR144053 trihydrochloride

    		Integrin Cardiovascular Disease
    GR 144053 trihydrochloride is a selective and non-peptic GPIIb/IIIa inhibitor (IC50=37 nM) .
    GR144053 trihydrochloride
  • HY-100007
    Vonoprazan
    3 Publications Verification

    TAK-438 free base

    		 Proton Pump Bacterial Endocrinology
    Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
    Vonoprazan
  • HY-106449
    Recoflavone

    DA-6034 free acid

    		 Others Inflammation/Immunology Cancer
    Recoflavone is a synthetic derivative of eupatilin that has a protective effect on gastric mucosa. Recoflavone has the potential to be used to research peptic ulcer disease.
    Recoflavone
  • HY-B1475
    Anisotropine bromide

    Octatropine bromide
    Anisotropine (Octatropine) bromide is an orally active anticholinergic muscarinic antagonist. Anisotropine bromide can inhibit gastric acid secretion and is used as an adjunct to peptic ulcers .
    Anisotropine bromide
  • HY-B1667
    Isopropamide iodide

    Isopropamide iodide is a long-acting quaternary anticholinergic agent. Isopropamide iodide is used in peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility .
    Isopropamide iodide
  • HY-W278232
    Urease-IN-6

    		Bacterial Infection
    Urease-IN-6 is a potent inhibitor of Urease with an IC50 of 14.2 μM. Urease-IN-6 can be used in study peptic and gastric ulcers .
    Urease-IN-6
  • HY-N7933
    Tetracosane

    ALKANE C24

    		 Apoptosis Inflammation/Immunology
    Tetracosane (ALKANE C24) is a natural product that can be found in Acrostichum aureum. Tetracosane hows cytotoxicity and induces Apoptosis. Tetracosane has the potential for the research of peptic ulcer .
    Tetracosane
  • HY-B0954A
    Oxyphencyclimine

    Oxyphencyclimine is an orally active muscarinic receptor (mAChR) antagonist. Oxyphencyclimine is effective in reducing ulceration index and increasing pepsin activity in rat gastric ulcer model. Oxyphencyclimine can be used in studies of peptic ulcer disease and gastrointestinal spasm .
    Oxyphencyclimine
  • HY-118283
    5-Hydroxylansoprazole
    1 Publications Verification

    AG1908

    		 Proton Pump Metabolic Disease
    5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric proton-pump inhibitor and is effective in the treatment of various peptic diseases .
    5-Hydroxylansoprazole
  • HY-17037A
    Pirenzepine

    LS 519 free base; Pirenzepin; Gastrozepin
    Pirenzepine (LS 519 free base) is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine shows anti-proliferative activity to cancer cells .
    Pirenzepine
  • HY-B0955R
    Oxethazaine (Standard)

    Oxetacaine (Standard)

    		 HBV Neurological Disease
    Oxethazaine (Standard) is the analytical standard of Oxethazaine. This product is intended for research and analytical applications. Oxethazaine (Oxetacaine), a precursor of phentermine acidic, is an acid-resistent and orally active analgesic agent. Oxethazaine (Oxetacaine) has the potential for the relief of pain associated with peptic ulcer disease or esophagitis .
    Oxethazaine (Standard)
  • HY-106789
    Plaunotol

    CS-684

    		 Bacterial Infection Inflammation/Immunology Cancer
    Plaunotol is an orally active acyclic diterpene alcohol. Plaunotol has antibacterial activity against Helicobacter pylori which causes peptic ulcer . Plaunotol inhibits tumor angiogenesis and cell proliferation. Plaunotol induces apoptosis by activation of caspase 8 and caspase 9 pathways. Plaunotol is a potential anticancer agent against colon cancer .
    Plaunotol
  • HY-B0644
    Sucralfate

    Sucrose octasulfate-aluminum complex

    		 Bacterial Infection Inflammation/Immunology Cancer
    Sucralfate (Sucrose octasulfate-aluminum complex) is a potent and orally active gastroprotectant with no systemic effects. Sucralfate inhibits peptic activity and binds to negatively charged subepithelial proteins exposed during mucosal injury, forming a viscous layer that protects the vascular bed and proliferative zone. Sucralfate is used for prevention and research of several gastrointestinal diseases in vivo .
    Sucralfate
  • HY-W003467R
    Rabeprazole Sulfide (Standard)

    		Proton Pump Bacterial Infection Inflammation/Immunology
    Rabeprazole Sulfide (Standard) is the analytical standard of Rabeprazole Sulfide. This product is intended for research and analytical applications. Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H +/K +)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment .
    Rabeprazole Sulfide (Standard)
  • HY-B1367
    Carbenoxolone disodium
    1 Publications Verification
    Carbenoxolone disodium is the active metabolite of Glycyrrhizic acid (HY-N0184) and the inhibitor of human 11β-HSD and bacterial 3α, 20β-HSD . Carbenoxolone disodium is an uncoupling agent for gap junctions and a potent inhibitor of Vaccinia virus replication . Carbenoxolone disodium is used for the study of peptic, esophageal and oral ulceration and inflammation. Carbenoxolone disodium inhibits Vaccinia virus replication.
    Carbenoxolone disodium
  • HY-120536
    HPi1

    		Bacterial Infection
    HPi1 is a potent, selective and orally active antimicrobial against Helicobacter pylori with an IC50 of 0.24 μM and an MIC of 0.08-0.16 μg/mL. HPi1 is inactive against other bacteria, including the gut commensals Lactobacillus casei, Lactobacillus reuteri, and Bifidobacterium longum .
    HPi1
  • HY-B1588S
    Carbenoxolone-d4

    		Amyloid-β HIV 11β-HSD Infection Neurological Disease Inflammation/Immunology
    Carbenoxolone-d4 is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].
    Carbenoxolone-d4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: